DelveInsight’s, “Sodium Channel Blockers - Pipeline Insight, 2022,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Sodium Channel Blockers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sodium Channel Blockers: Overview
Sodium-channel blockers comprise the Class I antiarrhythmic compounds according to the Vaughan-Williams classification scheme. These drugs bind to and block the fast sodium channels that are responsible for the rapid depolarization (phase 0) of fast-response cardiac action potentials. This type of action potential is found in non-nodal, cardiomyocytes (e.g., atrial and ventricular myocytes; purkinje tissue). Because the slope of phase 0 depends on the activation of fast sodium-channels and the rapid entry of sodium ions into the cell (Figure: Na+ in), blocking these channels decreases the slope of phase 0, which also leads to a decrease in the amplitude of the action potential.
Sodium Channel Blockers cross the blood-brain barrier and act through multiple mechanisms. They inhibit the gamma-aminobutyric acid (GABA) system (primarily lidocaine), activate the sodium ouabain-sensitive current, stimulate 5-TH2C receptors, antagonize H1 receptors and block all noradrenaline activating effect. It is through these actions that adrenergic stimulation occurs. These medications in large doses are also pro-convulsant through the above mechanisms.
Medications that act by sodium channel blockade have a wide variety of clinical applications. Broadly they include Vaughn Williams Class 1 antiarrhythmics, local anesthetics, many medications used to treat neuropathic pain (including tricyclic antidepressants (TCAs)), anticonvulsants, and cocaine. Complications of sodium channel blocker toxicity include cardiogenic shock, hypotension, bradycardia or tachycardia, cardiovascular collapse, respiratory depression, encephalopathy, status epilepticus, and death.
The companies and academics are working to assess challenges and seek opportunities that could influence Sodium Channel Blockers R&D. The therapies under development are focused on novel approaches for Sodium Channel Blockers.
This segment of the Sodium Channel Blockers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sodium Channel Blockers Emerging Drugs
Cenobamate: SK biopharmaceuticals
Cenobamate was discovered and developed by SK Biopharmaceuticals and SK life science. It is approved for Partial epilepsies. SK Biopharmaceuticals also has an exclusive licensing agreement with Ono Pharmaceutical to develop and commercialize cenobamate in Japan.
It is currently in Phase III stage of development for Tonic-clonic epilepsy and is being developed by SK biopharmaceuticals.
BIIB095: Biogen
BIIB095 is a voltage- and use- dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.
It is currently in Phase I stage of development for Neuropathic pain and is being developed by Biogen.
Further product details are provided in the report……..
This segment of the report provides insights about the different Sodium Channel Blockers drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 30+ key companies which are developing the Sodium Channel Blockers. The companies which have their Sodium Channel Blockers drug candidates in the most advanced stage, i.e. Phase III include, SK biopharmaceuticals.
DelveInsight’s report covers around 30+ products under different phases of clinical development like
Sodium Channel Blockers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sodium Channel Blockers therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium Channel Blockers drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Sodium Channel Blockers: Overview
Pipeline Therapeutics
Therapeutic Assessment
Sodium Channel Blockers– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Sodium Channel Blockers Collaboration Deals
Late Stage Products (Phase III)
Cenobamate: SK biopharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
P-1037: Parion Sciences
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Biogen: Biogen
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Research programme: NaV1.8 inhibitor pain therapeutics: Vertex Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Sodium Channel Blockers Key Companies
Sodium Channel Blockers Key Products
Sodium Channel Blockers- Unmet Needs
Sodium Channel Blockers- Market Drivers and Barriers
Sodium Channel Blockers- Future Perspectives and Conclusion
Sodium Channel Blockers Analyst Views
Sodium Channel Blockers Key Companies
Appendix
List of Table
Table 1: Total Products for Sodium Channel Blockers
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Sodium Channel Blockers
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Biogen
• Parion Sciences
• AlphaNavi Pharma
• Vertex Pharmaceuticals
• SK biopharmaceuticals
• UCB Biopharma
